Today officials from the Food and Drug Administration (FDA) and Pfizer will meet to discuss when and if recipients of the company's mRNA COVID-19 vaccine need a booster dose in the coming months given the emergence of the Delta (B1617.2) variant.
Last week the FDA and the Centers for Disease Control and Prevention (CDC) said so far there is not enough data to recommend a booster, but Pfizer cites small trial results and real-world evidence from Israel that show antibodies produced by the vaccine wane over a period of months and are bolstered with a third dose administered within 12 months of the original vaccine series.